Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Abemaciclib by Eli Lilly and Co for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma)....
Abemaciclib by Eli Lilly and Co for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Triple-Negative Breast Cancer (TNBC)....
Abemaciclib by Eli Lilly and Co for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer...
Abemaciclib by Eli Lilly and Co for Endometrial Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Endometrial Cancer. According to...
Abemaciclib by Eli Lilly and Co for Epithelial Ovarian Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Epithelial Ovarian Cancer. According...
Abemaciclib by Eli Lilly and Co for Peritoneal Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Peritoneal Cancer. According to...
Abemaciclib by Eli Lilly and Co for Fallopian Tube Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Fallopian Tube Cancer. According...
Abemaciclib by Eli Lilly and Co for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Transitional Cell Cancer (Urothelial...
Abemaciclib by Eli Lilly and Co for Metastatic Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Metastatic Breast Cancer. According...
Abemaciclib by Eli Lilly and Co for Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Breast Cancer. According to...
Abemaciclib by Eli Lilly and Co for Adipocytic Sarcoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma. According to...
Abemaciclib by Eli Lilly and Co for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)....
Abemaciclib by Eli Lilly and Co for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Renal Cell Carcinoma....
Abemaciclib by Eli Lilly and Co for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Transitional Cell Cancer (Urothelial...
Abemaciclib by Eli Lilly and Co for Metastatic Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Metastatic Breast Cancer. According...
Abemaciclib by Eli Lilly and Co for Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Breast Cancer. According to...